biotech · Huntington Disease · Alzheimer Disease · VYGR
Voyager Therapeutics
Voyager Therapeutics is a biotech organization headquartered in Lexington, USA. It trades on NYSE under ticker VYGR. Primary therapeutic focus areas include Huntington Disease, Alzheimer Disease, Alzheimer's Disease, Alz
Lexington, USA HQ
2014 Founded
168 Employees
Public company Type
VYGR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Lexington, USA
- Founded
- 2014
- Employees
- 168
- Programs
- 4
- Drugs
- 4
- Patents
- 31
VY7523
Phase 2 · small molecule · Alzheimer's Disease (AD)
VY7523 for Alzheimer's Disease (AD) is a Phase 2 program (small_molecule) at Voyager Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code VY7523-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Voyager Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Alzheimer's Disease (AD)
- Status
- active
- Trials
- 1